Morrisville, NC – Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies to cure cancer, today announced that it will present clinical progress on its lead program, IB-T101, at the American Association for Cancer Research (AACR) Annual Meeting 2025.
IB-T101 is an autologous CAR-T therapy targeting CD70, developed for patients with advanced clear cell renal cell carcinoma (ccRCC). The program is built on OUTLAST™, Inceptor’s proprietary platform designed to reprogram T cells for superior persistence and functionality in the hostile tumor microenvironment of solid tumors.
AACR 2025 Presentation Details:
Session: Phase I Clinical Trials in Progress
Date: Monday, April 28, 2025
Time: 2:00–5:00 PM CT
Location: Poster Board #6, Section 51
Abstract: CT111
Presenter: Max Richter, Director of Research, Inceptor Bio
“We’re proud to be advancing IB-T101 through clinical development and to share our progress with the oncology community at AACR,” said Matthias Schroff, Ph.D., CEO of Inceptor Bio. “Our OUTLAST™ platform is designed to solve the key limitations of cell therapies in solid tumors, and this marks an exciting step forward in our mission to bring durable, life-changing treatments to patients.”
About Inceptor Bio
Inceptor Bio, founded in May 2020 and headquartered in Research Triangle Park, NC, is dedicated to advancing next-generation cell and gene therapies to cure cancer. The company’s proprietary OUTLAST™ platform reprograms T cells to maintain stemness and effector function, addressing the unique challenges of treating solid tumors. Inceptor’s lead program, IB-T101, targets CD70 in clear cell Renal Cell Carcinoma (ccRCC) and represents a potentially best-in-class therapy. With a strong leadership team and strategic partnerships, Inceptor Bio is committed to advancing a pipeline of cutting-edge therapies to improve outcomes for patients with limited treatment options globally.
